Cardiomyopathies remain one of the most common inherited cardiac diseases in both human and veterinary patients. To date, well over 100 mutated genes are known to cause cardiomyopathies in humans with only a handful known in cats and dogs. This review highlights the need and use of personalized one-health approaches to cardiovascular case management and advancement in pharmacogenetic-based therapy in veterinary medicine. Personalized medicine holds promise in understanding the molecular basis of disease and ultimately will unlock the next generation of targeted novel pharmaceuticals and aid in the reversal of detrimental effects at a molecular level.
Keywords: Arrhythmogenic right ventricular cardiomyopathy (ARVC); Cats; Dilated cardiomyopathy (DCM); Dogs; Genetics; Hypertrophic cardiomyopathy (HCM); Pharmacogenetics; Pharmacogenomics.
Copyright © 2023 Elsevier Inc. All rights reserved.